On August 10, 2023, the Board of Directors (the ?Board?) of NeuroBo Pharmaceuticals, Inc. (the ?Company?) appointed Mr. Hyung Heon Kim, a member of the Board, as the Company?s Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer effective as of August 11, 2023. Mr. Kim has served as a member of the Board since July 2021. Mr. Kim previously served as General Counsel and a Senior Vice President of Dong-A ST (?Dong-A ST?) (which holds approximately 60% of the Company?s outstanding common stock), and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs.

Mr. Kim served as General Counsel of Dong-A ST since January 2018 and as a Vice President of Dong-A ST since December 2020. Mr. Kim previously served as Executive Director of Dong-A ST from January 2018 through December 2020. Prior to his roles with Dong-A ST, Mr. Kim was Head of International Legal Affairs for Dong-A Socio Holdings Co.

Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private Swiss-based provider of scientific research and development services. Prior to joining Dong-A Socio Group, Mr. Kim served as legal counsel to SK Energy Co.

Ltd. and SK Innovation Co. Ltd. from 2008 to 2011. Mr. Kim received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.

As disclosed in the Current Report on Form 8-K filed by the Company on January 12, 2023, the Company previously entered into an engagement letter with Korn Ferry US (the ?KF Agreement?) pursuant to which Mr. Joseph Hooker was appointed to serve as Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer of the Company. In connection with the appointment of Mr. Kim as the Chief Executive Officer and President as described above, on August 11, 2023 the Company terminated the KF Agreement and Mr. Hooker ceased to serve as Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer of the Company as of such date. The departure of Mr. Hooker was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.